NORDIC NANOVECTOR TO HOST CAPITAL MARKETS DAY IN OSLO ON 31 MAY 2016

Oslo, Norway, 23 May 2016

Nordic Nanovector ASA (OSE: NANO), a company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology, will host a Capital Markets Day on Tuesday, 31 May 2016 in Oslo.

CEO Luigi Costa, the senior management team and selected external speakers will share insights on Nordic Nanovector’s strategy, key achievements and market opportunities.

Venue:  Hotel Continental, Stortingsgaten 24-26, Oslo

Date:    31 May 2016

Time:    Registration and breakfast from 08:00 CEST

Agenda:

08:30 Opening remarks Luigi Costa, CEO
08:40 Welcome   Ludvik Sandnes, Chairman
08:50 NHL: How will emerging therapies change the treatment paradigm?     Prof. Pier Luigi Zinzani 
09:30 Betalutin®: A modern approach to treating NHL patients    Dr Arne Kolstad    
10:10 Q&A   
10:20 Coffee break     
10:40 Betalutin®'s opportunity in the treatment of NHL:     Marco Renoldi, CBO
          an insights-backed perspective      
11:00 Beyond Betalutin®: Exploring Nordic Nanovector’s    Jostein Dahle, CSO 
          R&D portfolio    
11:20 Executing on our corporate strategy   Luigi Costa, CEO & Tone Kvåle, CFO
11:50 Q&A & closing remarks Luigi Costa, CEO
12:00 Lunch  

Registration: e-mail to ir@nordicnanovector.com within 27th of May 2016

The presentations will be available at www.nordicnanovector.com in the section:  Investor Relations/Reports and Presentation/Presentations/2016 from following the meeting. No new material information will be presented.

Biographies of external speakers:

Dr Arne Kolstad is senior consultant in medical oncology and radiotherapy at Oslo University Hospital Radiumhospitalet and he also holds a research position funded by the Norwegian Cancer Society. He is chairman of the Norwegian Lymphoma Group and leader of Oslo University Hospital focus area Cancer Immunotherapy. His main scientific interests are radioimmunotherapy, cellular therapies and cancer vaccines in malignant lymphoma. He published two papers as first author in Blood in 2014, one as principal investigator of a Nordic radioimmunotherapy trial in mantle cell lymphoma and another as principal investigator of a cancer vaccine trial in follicular lymphoma. He was a visiting scientist in Mark Kaminski’s group at the University of Michigan in 1998-1999 and visiting professor in Ron Levy’s group at Stanford University in 2007-2008. He has published more than 60 original papers in international journals and was awarded the Ragnar Mørks prize for cancer research at Oslo University Hospital Radiumhospitalet in 2014. He was also awarded a prize for best original article at Oslo University Hospital in 2014. Dr Kolstad is a member of Nordic Nanovector’s Scientific Advisory Board.

Professor Pier Luigi Zinzani is Associate Professor of Haematology at the Institute of Haematology “L. e A. Seràgnoli” at the University of Bologna. He graduated in Medicine and Surgery from the University of Bologna in 1984, and obtained the speciality in Haematology from the same university in 1987. He was awarded a Post-Doctoral Fellowship in Medical Physics by the Roger Williams Cancer Center, Providence, RI, USA in 1989. Professor Zinzani is a member of the Italian Society of Haematology, the Italian Society of Experimental Haematology, the American Society of Hematology, and the American Society of Clinical Oncology, and has presented his research at more than 250 national and international meetings. He has written more than 445 peer-reviewed articles, mostly dedicated to Hodgkin lymphoma (HL), non-Hodgkin lymphomas (NHLs), and hairy cell leukaemia (HCL), and these have been published in journals such as Blood, the Journal of Clinical Oncology, Lancet Oncology, Haematologica and Annals of Oncology. He has been an Associate Editor of Annals of Oncology since January 2014. Professor Zinzani’s current research interests include clinical trial methodology, prognostic factors in NHL, HL, HCL, chronic lymphocytic leukaemia, and new drug development. Professor Zinzani is co-chair of Nordic Nanovector’s Scientific Advisory Board.

For further information, please contact:

Tone Kvåle, Chief Financial Officer

ir@nordicnanovector.com

Cell: +47 91 51 95 76  

International Media Enquiries

Mark Swallow/David Dible (Citigate Dewe Rogerson)

Tel: +44 207 282 2948/+44 207 282 2949

About Nordic Nanovector

Nordic Nanovector is a biotech company focusing on the development and commercialisation of novel targeted therapeutics in haematology and oncology. The Company’s lead clinical-stage product opportunity is Betalutin®, the first in a new class of Antibody-Radionuclide-Conjugates (ARC) designed to improve upon and complement current options for the treatment of non-Hodgkin Lymphoma (NHL). NHL is an indication with substantial unmet medical need and orphan drug opportunities, representing a growing market worth over $12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37 antibody (HH1) conjugated to a low intensity radionuclide (lutetium-177). The preliminary data has shown promising efficacy and safety profile in an ongoing Phase 1/2 study in a difficult-to-treat NHL patient population. The Company is aiming at developing Betalutin® for the treatment of major types of NHL with first regulatory submission anticipated in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets, while exploring potential distribution agreements in selected geographies. The Company is committed to developing its ARC pipeline to treat multiple selected cancer indications.

Further information about the Company can be found at www.nordicnanovector.com

This information is subject to duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act.

 

Tags:

About Us

About Nordic Nanovector ASA Nordic Nanovector is committed to develop and deliver innovative therapies to patients to address major unmet medical needs and advance cancer care. The company aspires to become a leader in the development of targeted therapies for haematological cancers.Nordic Nanovector’s lead clinical-stage candidate is Betalutin®, a novel CD37-targeting Antibody-Radionuclide-Conjugates (ARC) designed to advance the treatment of non-Hodgkin’s Lymphoma (NHL). NHL is an indication with substantial unmet medical need, representing a growing market forecast to be worth nearly USD 20 billion by 2024.The Company aims to rapidly develop Betalutin®, alone and in combination with other therapies, for the treatment of major types of NHL, targeting first regulatory submission in relapsed/refractory follicular lymphoma in 1H 2019. Nordic Nanovector intends to retain marketing rights and to actively participate in the commercialisation of Betalutin® in core markets.The Company is also advancing a pipeline of ARCs and other immunotherapies for multiple cancer indications.Further information about the Company can be found at www.nordicnanovector.com

Subscribe